5 reports of this reaction
9.6% of all APIS MELLIFERA reports
#1 most reported adverse reaction
AGRANULOCYTOSIS is the #1 most commonly reported adverse reaction for APIS MELLIFERA, manufactured by Boiron. There are 5 FDA adverse event reports linking APIS MELLIFERA to AGRANULOCYTOSIS. This represents approximately 9.6% of all 52 adverse event reports for this drug.
Patients taking APIS MELLIFERA who experience agranulocytosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
AGRANULOCYTOSIS is moderately reported among APIS MELLIFERA users, representing a notable but not dominant share of adverse events.
In addition to agranulocytosis, the following adverse reactions have been reported for APIS MELLIFERA:
The following drugs have also been linked to agranulocytosis in FDA adverse event reports:
AGRANULOCYTOSIS has been reported as an adverse event in 5 FDA reports for APIS MELLIFERA. This does not prove causation, but indicates an association observed in post-market surveillance data.
AGRANULOCYTOSIS accounts for approximately 9.6% of all adverse event reports for APIS MELLIFERA, making it one of the most commonly reported side effect.
If you experience agranulocytosis while taking APIS MELLIFERA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.